Culture and values

Passionate in the pursuit of life-changing treatments

Our team is pushing the boundaries of cancer therapy to deliver life-changing treatments to patients. Our employees enjoy a flexible, diverse, and dynamic working environment which actively promotes creativity, leadership and teamwork.

Our culture

We believe that everyone at Autolus has an important role to play in what we do, and we are committed to supporting all of our employees.

This is through learning and development programes, reward and recognition, hybrid working, employee resource groups and many other employee-focused initiatives.

As we continue to grow, our culture continues to evolve, with our values remaining at the heart of everything we do.

Our values have enabled us to agree how we will work together in a way that brings out the best in us all.

Our values were agreed together. We will live them together too.

Focus

Consistently delivering high quality with a sense of urgency.

Respect

Treating people as individuals and valuing their contribution.

Integrity

Operating by strong moral and ethical principles.

Breakthrough

Generating cutting-edge therapies that offer patients a longer, better future.

Employee testimonials

“Autolus was my first job after finishing university and I was instantly struck by the passion, motivation and drive of the talented group of people working here. I have been able to progress my career since I started working here in 2016 and it has opened my eyes to the exciting world of CAR T cell therapies. Being a part of building this organisation has been a valuable experience and I look forward to what the future brings at Autolus.”

Rebecca Chapman HR Business Partner

“When I had my interview, I was interested to hear about all the technologies and patents that Autolus were working on. I was also excited by the prospect of working in a dynamic environment in Research & Development, led by scientists (Dr Martin Pule and his team) who were full of brilliant ideas and top in the CAR T cell field.”

Tom Grothier PhD Student, Synthetic Biology
1/2